GLP-1 for Weight Loss and Diabetes
US$ 24.87
retatrutide triple agonist glp-1 gip glucagon phase 2 nejm 2023 Research Guide: What the Trial Data Reported (2026) Beyond GLP-1: Retatrutide's triple-agonist mechanism
Description
De Mesquita YLL et al
In the STEP 5 study, participants taking semaglutide lost an average of 15.2% of their body weight over two years, compared with 2.6% in the placebo group
Biomarker qualification: evidentiary framework
These findings can help in the search for miR-758 biomarkers that target important lipid metabolism pathways [175]
But for 2025H1, Lilly stands as the frontrunner
